why choose us

First received: November 03, 2023

Clinical Trial: An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

Study Status: Completed

Recruit Status: RECRUITING

Condition: Migraine Disorders

Study Type: OBSERVATIONAL


Official Title: A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine: the 'EEG Paradigm'

Brief Summary: This is a prospective, multi-center, unblinded study in patients with migraine (? 8 MMDs(monthly migraine days)/month) requiring preventive treatment.Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern).The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase as well as the Post Treatment (4 weeks).There are 2 sites in the U.S. participating, where a total of 20…

Read more